No Image Available

Drug infusion systems

SynchroMed™ II intrathecal pump

<p>The SynchroMed™ II programmable, implantable pump delivers drug to the intrathecal space via an implanted catheter.</p>

Contact a representative

Features

SynchroMed™ II pump

  • Offered in two sizes (20 mL or 40 mL) to create efficient refill intervals
  • Powerful long-lasting durability with diamond-like carbon coating that resists the wear from gear revolutions†
  • Designed to last up to seven years at up to 0.9 mL/day flow rate
  • ±0.3% repeatability — each pump precisely delivers a reliable and consistent amount of drug‡
  • Allows safe full-body access to 1.5- and 3.0-Tesla MRI.§ The pump is designed to resume programmed therapy after the scan◊ and does not need to be emptied prior to a scan, minimizing drug waste and procedural steps
A diagram of the SynchroMed™ II intrathecal pump showing the locations of the ports and suture loops.
  1. Catheter acess port
  2. Catheter port
  3. Suture loop
  4. Reservoir fill port

TM* Third-party brands are trademarks of their respective owners.

† Medtronic data on file.

‡ 95% confidence, 50% of the pumps have a flow rate repeatability of +/- 0.27% between successive 1 mL dispensed volumes within a refill cycle. 

§ Under specific conditions. Refer to product labeling for full list of conditions.

◊ Requires interrogation to confirm pump status.

  1. Hamza M, Doleys D, Wells M, et al. Prospective study of 3-year follow-up of low dose intrathecal opioids in the management of chronic nonmalignant pain. Pain Med. 2012;13:1304–1313.
  2. Hatheway J.A., Bansal M., Nichols-Ricker C.I. 2020. Systemic Opioid Reduction and Discontinuation Following Implantation of Intrathecal Drug-Delivery Systems for Chronic Pain: A Retrospective Cohort Analysis. Neuromodulation. 2020; 23: 961–969.
  3. Hatheway JA, et al. Systemic opioid elimination after implantation of an intrathecal drug delivery system significantly reduced health-care expenditures. Neuromodulation. 2015;18(3):207–13.
  4. Perruchoud et al. Management of Cancer-Related Pain With Intrathecal Drug Delivery: A Systematic Review and Meta-Analysis of Clinical Studies. Neuromodulation. 2022; S1094-7159(21)06969-5.
  5. Stearns et al. Intrathecal Drug Delivery Systems for Cancer Pain: An Analysis of a Prospective, Multicenter Product Surveillance Registry. Anesth Analg. 2020; 130(2):289–297. 
  6. Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug related toxicity, and survival. J Clin Oncol. 2002;20:4040–4049.

This product is licenced with Health Canada as Synchromed II infusion system on Health Canada licence number 63074.